Cross Cancer Institute ( Site 0057)

Edmonton, Alberta T6G 1Z2

0 studies enrolling now · 1 studies all time

What they study most

Melanoma

Studies at this site

• Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) — Running, not enrolling